---
date: "2024-01-13 07:28:43" # 2021-07-14
title: "TG Therapeutics (NASDAQ:TGTX) Rating Upgraded to Buy: Positive Outlook for Stock Revealed in Research Report"
# image: "images/plots/{{titleSlag}}.png"
author: "justin-guese"
draft: false
---
tickers: <a href='https://finance.yahoo.com/quote/TGTX' target='_blank'>TGTX</a>, <a href='https://finance.yahoo.com/quote/MCQEF' target='_blank'>MCQEF</a>, <a href='https://finance.yahoo.com/quote/PNC' target='_blank'>PNC</a> 

source: <a href='https://www.defenseworld.net/2024/01/13/tg-therapeutics-nasdaqtgtx-rating-increased-to-buy-at-stocknews-com.html' target='_blank'>Stocknews.com</a>

#### tickers affected by this

| ticker | polarity | why? |
|------------|------------|------------|
| TGTX | positively | The upgrade to a "buy" rating by StockNews.com, along with the positive earnings report and support from various analysts, indicates that TGTX's stock is expected to experience a positive impact in the market. |
| MCQEF | positively | Based on the limited information provided, it is not possible to determine why the ticker MCQEF would be affected positively by the article. |
| PNC | positively | PNC Financial Services Group (PNC) is expected to be positively affected by the upgraded rating of TG Therapeutics (TGTX) as PNC is mentioned as one of the institutional investors that increased its position in TG Therapeutics during the third quarter, indicating potential gains for PNC's investment in the company. |



#### our strategies and bots using these tickers

None so far...

## summary

## TG Therapeutics Rating Upgraded to "Buy" by StockNews.com

TG Therapeutics (NASDAQ:TGTX) has received an upgrade from StockNews.com, changing its rating from "hold" to "buy" in a recent research report. The company has also been the subject of various other research reports. Jefferies Financial Group reaffirmed its "buy" rating and set a price target of $23.00, while JPMorgan Chase & Co. upped its price objective for TG Therapeutics to $23.00 and gave the stock an "overweight" rating. B. Riley lowered their price target to $24.00, but still maintained a "buy" rating. HC Wainwright also increased its price target to $45.00 and gave the stock a "buy" rating. Overall, the stock has an average rating of "Moderate Buy" and an average price target of $25.14, according to data from MarketBeat.

The stock opened at $15.77 on Thursday and has a fifty-day moving average of $15.05 and a 200-day moving average of $13.55. TG Therapeutics has a market capitalization of $2.39 billion, a price-to-earnings ratio of -56.32, and a beta of 2.33. The company recently announced its earnings results for the quarter, reporting $0.73 earnings per share, which beat analysts' consensus estimates of $0.29 by $0.44. TG Therapeutics also saw a significant increase in quarterly revenue, reaching $165.80 million compared to analyst estimates of $23.91 million. However, the company still recorded a negative net margin of 13.65% and a negative return on equity of 35.58%. Despite these results, equities research analysts predict that TG Therapeutics will post earnings per share of 0.06 for the current year.

In terms of insider activity, CFO Sean A. Power recently sold 47,867 shares of TG Therapeutics stock, totaling $809,430.97. Director Laurence N. Charney also sold 17,500 shares of the company's stock, totaling $333,025.00. In total, insiders own 9.20% of the company's stock.

Several large institutional investors have made changes to their positions in TG Therapeutics. RFP Financial Group LLC purchased a new stake in the company, while PNC Financial Services Group Inc. increased its position by 131.7% during the third quarter. Macquarie Group Ltd. and Coppell Advisory Solutions LLC also acquired stakes in the company during the second quarter. Additionally, Nemes Rush Group LLC bought a new position in TG Therapeutics during the same period. These institutional investors now collectively own a significant portion of the company's stock, amounting to 57.92%.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. Its key product, BRIUMVI, is an anti-CD20 monoclonal antibody used to treat adult patients with relapsing forms of multiple sclerosis. 

Overall, the upgrade from StockNews.com to a "buy" rating has sparked optimism in the market for TG Therapeutics. The company's positive earnings report and the support from various analysts have also contributed to the increased confidence in its stock.